Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate
Authors:
- Wen-Hsiang ChenWCWen-Hsiang Chen
- Lanying DuLDLanying Du
- Shivali M ChagSCShivali M Chag
- Cuiqing MaCMCuiqing Ma
- Nancy TricocheNTNancy Tricoche
- Xinrong TaoXTXinrong Tao
- Christopher A SeidCSChristopher A Seid
- Elissa M HudspethEHElissa M Hudspeth
- Sara LustigmanSLSara Lustigman
- Chien-Te K TsengCTChien-Te K Tseng
- Maria Elena BottazziMBMaria Elena Bottazzi
- Peter J HotezPHPeter J Hotez
Open Access
- 30 December 2013
- journal article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (3) , 648-658
Abstract
Development of vaccines for preventing a future pandemic of severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV) and for biodefense preparedness is urgently needed. Our previous studies have shown that a candidate SARS vaccine antigen consisting of the receptor-binding domain (RBD) of SARS-CoV spike protein can induce potent neutralizing antibody responses and protection against SARS-CoV challenge in vaccinated animals. To optimize expression conditions for scale-up production of the RBD vaccine candidate, we hypothesized that this could be potentially achieved by removing glycosylation sites in the RBD protein. In this study, we constructed two RBD protein variants: 1) RBD193-WT (193-aa, residues 318–510) and its deglycosylated forms (RBD193-N1, RBD193-N2, RBD193-N3); 2) RBD219-WT (219-aa, residues 318–536) and its deglycosylated forms (RBD219-N1, RBD219-N2, and RBD219-N3). All constructs were expressed as recombinant proteins in yeast. The purified recombinant proteins of these constructs were compared for their antigenicity, functionality and immunogenicity in mice using alum as the adjuvant. We found that RBD219-N1 exhibited high expression yield, and maintained its antigenicity and functionality. More importantly, RBD219-N1 induced significantly stronger RBD-specific antibody responses and a higher level of neutralizing antibodies in immunized mice than RBD193-WT, RBD193-N1, RBD193-N3, or RBD219-WT. These results suggest that RBD219-N1 could be selected as an optimal SARS vaccine candidate for further development.Keywords
This publication has 31 references indexed in Scilit:
- Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine DevelopmentJournal of Virology, 2013
- A Critical HA1 Neutralizing Domain of H5N1 Influenza in an Optimal Conformation Induces Strong Cross-ProtectionPLOS ONE, 2013
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccineBiochemical and Biophysical Research Communications, 2004
- Glycosylation of Immunodominant Linear Epitopes in the Carboxy-Terminal Region of the Caprine Arthritis-Encephalitis Virus Surface Envelope Enhances Vaccine-Induced Type-Specific and Cross-Reactive Neutralizing Antibody ResponsesJournal of Virology, 2004
- Cloning, Yeast Expression, Isolation, and Vaccine Testing of RecombinantAncylostoma‐Secreted Protein (ASP)–1 and ASP‐2 fromAncylostoma ceylanicumThe Journal of Infectious Diseases, 2004
- A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2Journal of Biological Chemistry, 2004
- Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003The Lancet, 2003
- Coronavirus as a possible cause of severe acute respiratory syndromeThe Lancet, 2003
- Filamentous fungi as cell factories for heterologous protein productionTrends in Biotechnology, 2002